Comparative Pharmacology
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE versus TRINALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE versus TRINALIN.
FEXOFENADINE HYDROCHLORIDE vs TRINALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective peripheral H1-receptor antagonist; inhibits histamine release from mast cells and basophils, reducing allergic symptoms without significant central nervous system penetration.
TRINALIN is a combination of azatadine, a first-generation antihistamine that antagonizes histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and reducing nasal congestion.
60 mg orally twice daily or 180 mg orally once daily; maximum 180 mg/day.
One tablet (azatadine 1 mg/pseudoephedrine 120 mg) orally every 12 hours. Not to exceed 2 tablets in 24 hours.
None Documented
None Documented
14.4 hours in healthy adults; prolonged in renal impairment (up to 58 hours in end-stage renal disease) requiring dose adjustment.
Terminal elimination half-life approximately 20-30 hours; clinical context: allows twice-daily dosing for sustained decongestant effect
Primarily fecal (80%) with approximately 11% renal excretion of unchanged drug. Biliary excretion contributes to fecal elimination.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30%
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant